VANCOUVER, Canada and MENLO PARK, Calif., May 20, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) announced today that Jeffrey Bacha, president and CEO, will present at the Second Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 in New York City at the Grand Hyatt Hotel.
The Company's presentation is scheduled to begin at 11:30 a.m. EDT and will be available via a live webcast. To access the webcast, go to: https://lark.twst.com/pay/webcasting/marcum/cart/show.html.
DelMar Pharmaceuticals Recent 2013 Highlights:
- April: Presented encouraging data from ongoing Phase I/II glioblastoma multiforme (GBM) clinical trial with VAL-083 at the American Association of Cancer Research (AACR)Annual Meeting
- March: Named to Rocket Builders' 2013 "Ready to Rocket" list
- March: Announced completion of $10.5 million oversubscribed offering
- February: Appointment John K. Bell, chairman of Onbelay Capital Inc., to board of directors
- January: Completed $5.4 million first closing and public listing transaction
- January: Received European orphan drug designation for VAL-083 for the treatment of glioma
For more information and registration, please visit the conference website: http://www.marcumllp.com/microcap
About DelMar Pharmaceuticals
DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme, the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action. For more info, please visit http://www.delmarpharma.com/.
About Marcum LLP
Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation. Ranked among the top 15, Marcum LLP offers the resources of 1,000 professionals, including over 125 partners, in more than 20 offices throughout New York, New Jersey, Massachusetts, Connecticut, Pennsylvania, California, Florida, Grand Cayman and China. Headquartered in New York City, the Firm's presence runs deep with full-service offices strategically located in major business markets. Marcum is a member of the Marcum Group, an organization providing a comprehensive range of professional services spanning accounting and advisory, technology solutions, wealth management, and executive and professional recruiting. The Marcum Group companies include Marcum LLP; Marcum Technology LLC; Marcum Search LLC; Marcum Financial Services LLC; Marcum Bernstein & Pinchuk LLP; MarcumBuchanan Associates LLC; and Marcum Cronus Partners LLC.
Investor or Corporate Contacts:
Jeffrey A. Bacha
President & CEO
Booke & Company Investor Relations
SOURCE Marcum LLP